Tadese Bekana K, You Xuedan, Ndao Tidiane, Tota Joseph E, Chen Ya-Ting, Chowdhary Alisa, Pan Jia, Costa Ana C, Mugo Nelly
Merck & Co., Inc., Rahway, New Jersey, USA.
Adelphi Values PROVE™, Adelphi Mill, Bollington, UK.
J Med Virol. 2025 Apr;97(4):e70274. doi: 10.1002/jmv.70274.
Human papillomavirus (HPV) is associated with a significant global burden of precancerous lesions and cancer. People with HIV (PWH) are at higher risk of HPV infection and HPV-related diseases. This systematic review was conducted to synthesize data on the burden of HPV infection and HPV-related diseases among PWH. Studies published between January 2018-June 2023 were sourced from databases and conferences. Included were 221 publications containing epidemiological data on HPV infections and the clinical burden of HPV-related diseases among PWH. The burden varied by geographical region, age, sex, and sexual orientation. Compared to people without HIV (PWoH), PWH had higher prevalence and incidence of HPV infection and HPV-related diseases. Among PWH, the prevalence of anal HPV infection ranged between 44% and 83%; men had a higher prevalence and incidence of anogenital warts than women. The incidence of anal HPV infection was over two-fold greater among transgender women with HIV and men who have sex with men with HIV than among their respective counterparts without HIV. Incident HPV-related anal cancer was up to two-fold higher among PWH than PWoH, and incident cervical cancer was up to six times higher among women with HIV than those without. The most prevalent high-risk (hr) HPV genotypes with HPV-related disease were vaccine genotype HPV16/18/52/58. HPV35 was one of the most prevalent genotypes with anal or cervical HPV infection among PWH of African descent. PWH also have a higher burden of concurrent HPV infections and HPV-related diseases. This study calls for strengthening appropriate HPV vaccine delivery and increasing vaccine uptake among this high-risk group, potentially by integrating HPV vaccination with routine HIV care.
人乳头瘤病毒(HPV)与全球范围内大量的癌前病变和癌症负担相关。艾滋病毒感染者(PWH)感染HPV及患HPV相关疾病的风险更高。本系统评价旨在综合关于艾滋病毒感染者中HPV感染及HPV相关疾病负担的数据。2018年1月至2023年6月期间发表的研究来自数据库和会议。纳入了221篇包含艾滋病毒感染者中HPV感染的流行病学数据以及HPV相关疾病临床负担的出版物。负担因地理区域、年龄、性别和性取向而异。与未感染艾滋病毒的人(PWoH)相比,艾滋病毒感染者HPV感染及HPV相关疾病的患病率和发病率更高。在艾滋病毒感染者中,肛门HPV感染的患病率在44%至83%之间;男性肛门生殖器疣的患病率和发病率高于女性。感染艾滋病毒的变性女性和男男性行为艾滋病毒感染者中肛门HPV感染的发病率比未感染艾滋病毒的相应人群高出两倍多。艾滋病毒感染者中HPV相关肛门癌的发病率比未感染艾滋病毒的人高出两倍,感染艾滋病毒的女性中宫颈癌的发病率比未感染艾滋病毒的女性高出六倍。与HPV相关疾病最常见的高危(hr)HPV基因型是疫苗基因型HPV16/18/52/58。HPV35是非洲裔艾滋病毒感染者中肛门或宫颈HPV感染最常见的基因型之一。艾滋病毒感染者同时感染HPV及患HPV相关疾病的负担也更高。本研究呼吁加强适当的HPV疫苗接种,并提高这一高危人群的疫苗接种率,可能通过将HPV疫苗接种与常规艾滋病毒护理相结合来实现。